Lansing, Michigan, May 20, 2026, 07:05 (EDT)
Amy Rocklin, who was Neogen Corp.’s chief legal officer, turned 35,183 restricted stock units into common shares and had 10,241 of those shares held back for taxes, according to a U.S. securities filing. Rocklin ended up with 82,182 shares after the May 18 trades.
Neogen’s latest filing drew attention since it was made just weeks after Rocklin exited the Lansing-based food and animal safety group. Neogen is still trying to stabilize its main business following bumpy quarters and recent portfolio changes. According to the filing, the shares were the accelerated part of Rocklin’s outstanding awards when she left on March 31.
The transaction didn’t show up as an open-market sale. Restricted stock units (RSUs) are share grants that turn into stock if certain conditions are satisfied. Here, shares were sent to the company to handle tax withholding for the stock grant.
Neogen was last trading at $8.35 ahead of the regular U.S. open on Wednesday, putting its market cap near $1.8 billion. The stock has struggled as investors look at spending cuts while some units see weaker sales.
Neogen’s filing comes after a legal leadership change. The company named Jennifer Evans Stacey chief legal and compliance officer and board secretary on April 8. CEO Mike Nassif said her experience would help drive “organic growth through innovation” and upcoming deals. Stacey said Neogen must have “strong governance and a clear focus on execution.” Business Wire
Neogen posted fiscal Q3 revenue of $211.2 million in April, a drop of 4.4% from last year. Food Safety sales rose 2.6%, while Animal Safety sank 20.1%. Nassif said Neogen is working to “stabilize and strengthen” the business, but noted there were problems with third-party suppliers in the Animal Safety group. Neogen
The competitive landscape is shifting. Neogen reached a deal in March to sell its global genomics business to Zoetis for $160 million. That would send an animal genetics unit to a bigger animal-health player and sharpen Neogen’s focus on food and animal safety. Nassif said the move would “accelerate de-leveraging and improve profitability.” Neogen
The Form 4 gives a clearer line of sight, but execution risk for Neogen remains. The company still faces Animal Safety supply issues, has to manage its Petrifilm manufacturing shift, and must meet regulatory and closing hurdles on the Zoetis deal. Any of these could alter how fast margins or debt improve.
For investors, the filing clarifies that Rocklin’s reported share moves were related to her award vesting and paying taxes after leaving, and not a direct market sale. The bigger question is still whether Neogen can use its restructuring, new leaders and asset sales to drive more stable sales growth.
